JWM
NRSN icon

Jessup Wealth Management’s NeuroSense Therapeutics NRSN Stock Holding History

Jessup Wealth Management’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-500
Closed -$385 – 250
2025
Q4 		$385 Buy
+500
New +$526 ﹤0.01% 361

Other funds holding NRSN

YAG
Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $9.32B AUM 33.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jessup Wealth Management's NRSN Position: Q1 2026 in Review

Jessup Wealth Management sold out of NeuroSense Therapeutics (NRSN) in Q1 2026, closing a stake of 500 shares — an estimated $385 sold.

Jessup Wealth Management first reported a position in NRSN in Q4 2025 and held it in 1 quarter. The position peaked at $385 in Q4 2025. 13 funds tracked by Wall St. Rank hold NRSN as of Q1 2026.

  • Jessup Wealth Management reported no remaining NeuroSense Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jessup Wealth Management sold 500 NeuroSense Therapeutics shares in Q1 2026, an estimated $385.
  • Jessup Wealth Management first reported a position in NeuroSense Therapeutics in Q4 2025 and held it in 1 quarter.
  • Jessup Wealth Management's NeuroSense Therapeutics position peaked at $385 in Q4 2025.
  • 13 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q1 2026.

Based on Jessup Wealth Management's 13F filing for Q1 2026, filed 15 May 2026.